Chronic lymphocytic leukemia (CLL) Clinical Trials
Recruiting chronic lymphocytic leukemia (cll) studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.
Clinical trials study new ways to prevent, detect, or treat chronic lymphocytic leukemia (cll). Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting chronic lymphocytic leukemia (cll) studies with sites across the US; use the location tools to find ones near you.
What to expect
- Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
- Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
- No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.
Recruiting chronic lymphocytic leukemia (cll) trials
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway
Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Evaluation of Skin Tests in Biotherapy Allergies
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Mosunetuzumab for CLL MRD Clearance
Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Time Restricted Eating in Haematological Malignancies
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
64Cu-LLP2A for Imaging Hematologic Malignancies
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia Patients
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Biological and Clinical Efficacy of Shingrix in Patients With CLL
Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia Patients
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Familial B-cell Lymphoproliferative Disorders
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) clinical trials — common questions
Are chronic lymphocytic leukemia (cll) clinical trials free to join?
Yes. Participating in a chronic lymphocytic leukemia (cll) clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.
Who can join a chronic lymphocytic leukemia (cll) clinical trial?
Each chronic lymphocytic leukemia (cll) study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.
How do I find a chronic lymphocytic leukemia (cll) trial near me?
Use the location controls above. We'll show recruiting chronic lymphocytic leukemia (cll) trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.
How many chronic lymphocytic leukemia (cll) trials are recruiting right now?
We're currently tracking roughly 73 recruiting chronic lymphocytic leukemia (cll) trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.
Looking for a specific location? Browse trials by city and state.